Prothena Corporation plc kept at Hold after mixed phase 2 results; key phase 3 readouts expected 2029. Click for this updated ...

Streamlining of selected non‑strategic early-stage programs completed, consistent with previously announced three-year ...

AGOURA HILLS, Calif., Sept. 12, 2025 (GLOBE NEWSWIRE) -- via IBN -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("OTLC" or the "Company"), a clinical-stage biopharmaceutical company developing ...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing ...

Seres has finalized the protocol for the Phase 2 study of SER-155 in patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT) with the FDA and has advanced key study startup ...

Nov 7, 2025 – Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the launch of its innovative ...

Precision BioSciences Sets Strategic Priorities for 2026 Focused on Continued Advancement of Clinical-Stage Programs PBGENE-HBV for Chronic Hepatitis B and PBGENE-DMD for Duchenne Muscular Dystrophy ...

Novartis’ RNA production facility in Schweizerhalle, Switzerland. Novartis is acquiring Avidity Biosciences for approximately $12 billion, in a deal designed to bolster the buyer’s neuroscience ...

The path from promising scientific insight to an Investigational New Drug (IND) application is both exhilarating and ...